Sangamo Therapeutics, Inc.
SGMO
$0.7389
$0.04726.82%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 565.52% | 239.92% | -67.20% | -74.04% | -94.38% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 565.52% | 239.92% | -67.20% | -74.04% | -94.38% |
| Cost of Revenue | -38.55% | -50.56% | -51.61% | -43.53% | -33.75% |
| Gross Profit | 86.14% | 80.11% | 0.93% | -95.13% | -341.76% |
| SG&A Expenses | -22.62% | -29.01% | -33.70% | -31.67% | -26.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.98% | -46.05% | -47.91% | -41.10% | -32.17% |
| Operating Income | 71.06% | 68.58% | 18.15% | -20.54% | -102.53% |
| Income Before Tax | 74.45% | 76.11% | 62.68% | 46.92% | -21.65% |
| Income Tax Expenses | -116.50% | 97.17% | 96.71% | 99.74% | 120.24% |
| Earnings from Continuing Operations | 74.64% | 75.78% | 62.01% | 45.96% | -25.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.64% | 75.78% | 62.01% | 45.96% | -25.78% |
| EBIT | 71.06% | 68.58% | 18.15% | -20.54% | -102.53% |
| EBITDA | 71.88% | 68.87% | 10.87% | -36.23% | -124.04% |
| EPS Basic | 79.44% | 79.41% | 64.66% | 48.16% | -16.34% |
| Normalized Basic EPS | 75.54% | 73.20% | 18.63% | -27.40% | -97.13% |
| EPS Diluted | 78.78% | 78.91% | 64.18% | 48.23% | -15.24% |
| Normalized Diluted EPS | 75.38% | 73.06% | 18.57% | -27.31% | -96.49% |
| Average Basic Shares Outstanding | 21.20% | 18.79% | 15.07% | 12.49% | 11.04% |
| Average Diluted Shares Outstanding | 22.01% | 19.63% | 15.82% | 13.25% | 10.93% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |